HEART score sensitivity 0.96 vs GRACE 0.88 for 30-day MACE in ED chest pain

This systematic review and meta-analysis evaluated the diagnostic performance of the HEART score versus the GRACE score in emergency department (ED) patients with acute chest pain. The analysis pooled data from a total sample size of 14,862 patients across various settings, focusing on the emergency department population. The primary outcome was 30-day major adverse cardiac events (MACE), defined as death, myocardial infarction, and urgent revascularization.

The intervention was the HEART score, and the comparator was the GRACE score. Specific dosing or protocol details for these scores were not reported in the input. The follow-up period for all outcomes was 30 days.

For the primary outcome, the HEART score demonstrated significantly higher sensitivity than the GRACE score, with an effect size of 0.96 (95% CI: 0.94-0.98) versus 0.88 (95% CI: 0.85-0.91). The ratio for sensitivity was 1.09 (95% CI: 1.05-1.14). The HEART score also showed a lower negative likelihood ratio (NLR) of 0.08 (95% CI: 0.03-0.17) compared to the GRACE score's NLR of 0.42 (95% CI: 0.39-0.46). However, the HEART score had lower specificity (0.50, 95% CI: 0.41-0.60) than the GRACE score (0.61, 95% CI: 0.58-0.64). The area under the curve (AUC) for discriminative power was superior for the HEART score at 0.80 (95% CI: 0.77-0.84) versus 0.72 (95% CI: 0.69-0.75) for the GRACE score, with a ratio of 1.11 (95% CI: 1.07-1.15).

Key secondary outcomes included subgroup analysis in Eastern populations, which confirmed the HEART score's advantage in sensitivity, with a sensitivity ratio of 1.57 (95% CI: 1.27-1.93). No other secondary outcomes were reported.

Safety and tolerability findings were not reported for either score, including adverse events, serious adverse events, and discontinuations.

These results can be compared to prior landmark studies in risk stratification for acute chest pain, though specific comparisons were not detailed in the input. The HEART score's higher sensitivity aligns with its established role in identifying low-risk patients for safe discharge.

Key methodological limitations include the critical need for standardization of troponin assays and MACE definitions for future implementation, as noted in the limitations section. Potential biases were not explicitly reported, but heterogeneity in study designs and populations could influence results.

Clinical implications are that the HEART score supports its utility for safe discharge of low-risk individuals, while the GRACE score's higher specificity may aid in identifying high-risk cases requiring intervention. This informs practice decisions by highlighting the trade-offs between sensitivity and specificity for risk stratification.

Unanswered questions remain regarding the optimal use of these scores in specific subpopulations, the impact of standardized protocols, and long-term outcomes beyond 30 days.